A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $22 to $43
JP Morgan Downgrades RxSight to Underweight, Lowers Price Target to $17
RxSight Is Maintained at Equal-Weight by Wells Fargo
RxSight Downgraded to Underperform From Buy at BofA
RxSight Analyst Ratings
Stifel Nicolaus Sticks to Their Hold Rating for RxSight (RXST)
RxSight's Growth Potential Amid Challenges: A Buy Recommendation by David Saxon
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $36
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $36
RxSight Is Maintained at Buy by B of A Securities
Stifel Maintains RxSight(RXST.US) With Hold Rating, Cuts Target Price to $28
RxSight Price Target Cut to $28.00/Share From $33.00 by Stifel
RxSight Analyst Ratings
Stifel Maintains Hold on RxSight, Lowers Price Target to $28
Jefferies Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $50
Promising Growth and Competitive Edge: A Buy Rating for RxSight
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $42
Morgan Stanley Sticks to Their Buy Rating for RxSight (RXST)
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $33 to $50
RxSight Is Maintained at Equal-Weight by Wells Fargo